Lynetta J. Jobe

TL;DR: Use of pramlintide in addition to insulin in patients with type 1 and type 2 diabetes was associated with modest reductions in HbA(1c) and the incidence of hypoglycemia in the first 4 weeks of therapy was 2 to 4 times greater with pramsintide compared with placebo; thus, the manufacturer recommends reducing the dose of premeal insulin by 50% when starting pramlintide.

TL;DR: Mechanical interventions such as gradually restoring blood flow or applying postconditioning may be used independently in or conjunction with various cardioprotective pharmaceuticals in an integrated strategy of reperfusion therapeutics to reduce postischemic injury.

TL;DR: Pramlintide is an amylin analog that was FDA approved for the treatment of type 1 and type 2 diabetes and results in modest reduction of A1C and the most frequent side effects are hypoglycemia and nausea.

TL;DR: Although TNF-alpha antagonism did not prevent the initial ventricular dilatation at 3 wk postfistula, etanercept was effective at significantly attenuating the subsequent ventricular hypertrophy, dilatations, and increased compliance at 8 wkPostfistulas, demonstrating that treatment with etanorcept can attenuate the progression to heart failure.

TL;DR: Although the most recent American Diabetes Association guidelines recommended a GLP-1 agonist along with metformin as a second-tier therapy for type 2 diabetes, liraglutide should be considered for patients who cannot tolerate first-line agents or if an additional agent is needed to help reach target HbA(1c) goals.